Insmed presents new data on respiratory treatments at ATS conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 19 2025
0mins
Should l Buy INSM?
Insmed Inc's stock rose by 5.34% as it crossed above the 5-day SMA, despite the broader market decline. The company presented six abstracts at the 2026 American Thoracic Society International Conference, showcasing advancements in respiratory disease treatments. Notably, the Phase 3b ENCORE study highlighted ARIKAYCE®'s potential early application for Mycobacterium avium complex lung infections, which could significantly change treatment protocols.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INSM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INSM
Wall Street analysts forecast INSM stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 137.090
Low
162.00
Averages
219.50
High
263.00
Current: 137.090
Low
162.00
Averages
219.50
High
263.00
About INSM
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Insmed to Announce Q1 Earnings on May 7th
- Earnings Announcement: Insmed (INSM) is set to release its Q1 earnings on May 7th before market open, with consensus EPS estimate at -$0.98 and revenue estimate at $300.8 million, which could provide some support for the stock price if met.
- Historical Performance: Over the past year, Insmed has beaten EPS estimates 50% of the time and revenue estimates 75% of the time, indicating a relatively strong performance in managing market expectations, which may bolster investor confidence.
- Estimate Revision Trends: In the last three months, EPS estimates have seen 2 upward revisions and 5 downward revisions, while revenue estimates have experienced 4 upward revisions and 3 downward revisions, reflecting market divergence on the company's future performance, warranting close attention to the earnings results.
- Pipeline Developments: Despite setbacks in the mid-stage trial for a skin disorder candidate, the potential label expansion for ARIKAYCE is viewed as a positive signal, which could provide new momentum for the company's future growth and enhance market expectations for its product pipeline.
See More
Insmed Partners with Ty Pennington to Raise Awareness of Bronchiectasis
- Initiative Launch: Insmed collaborates with Emmy-winning host Ty Pennington to launch the 'Suspect Bronchiectasis' educational initiative aimed at enhancing awareness and diagnosis of bronchiectasis, helping patients better understand their respiratory symptoms.
- Symptom Overlap Issue: Symptoms of bronchiectasis often overlap with chronic obstructive pulmonary disease (COPD) or asthma, leading many patients to miss timely diagnoses, highlighting the need for deeper analysis of respiratory symptoms.
- Personal Story Sharing: Pennington shares his experience caring for his mother, who has battled bronchiectasis for nearly 20 years, aiming to inspire more individuals to focus on their health and engage in deeper conversations with their healthcare providers.
- Company Mission Reinforcement: Insmed's Chief Medical Officer, Dr. Flammer, emphasizes that increasing awareness of bronchiectasis helps patients communicate more confidently with doctors, thereby accelerating the diagnostic process and improving patient quality of life.
See More
Insmed Launches Educational Initiative for Bronchiectasis Awareness
- Initiative Launch: Insmed collaborates with Emmy-winning host Ty Pennington to launch the 'Suspect Bronchiectasis' initiative, aimed at raising public awareness and promoting early diagnosis of bronchiectasis to improve patient quality of life.
- Symptom Overlap Issue: Symptoms of bronchiectasis often overlap with chronic obstructive pulmonary disease (COPD) or asthma, leading to many patients going unrecognized for years, highlighting the importance of understanding respiratory symptoms for timely treatment.
- Public Engagement Boost: Ty Pennington increases visibility for this chronic lung condition by sharing his experience caring for his mother, encouraging more individuals to pay attention to their health and consult pulmonologists for necessary testing.
- Importance of Health Education: This initiative not only raises awareness of bronchiectasis but also emphasizes the significance of communicating with healthcare professionals, aiming to reduce the long-term impact of the disease through early diagnosis and intervention.
See More
Insmed Presents New Data Supporting BRINSUPRI® Impact on Respiratory Symptoms
- Research Presentation: Insmed will present six abstracts at the 2026 American Thoracic Society International Conference, showcasing the company's ongoing innovation and commitment in the respiratory disease sector.
- Clinical Trial Advancements: The Phase 3b ENCORE study will highlight ARIKAYCE®'s potential early application in treating patients with newly diagnosed Mycobacterium avium complex lung infections, which could alter existing treatment pathways.
- Quality Improvement Funding: Insmed is providing an independent research grant to the American Thoracic Society aimed at improving bronchiectasis diagnosis, expected to enhance patient care quality by identifying misdiagnosed patients through electronic health record studies.
- New Drug Development Updates: Investigational treprostinil palmitil inhalation powder (TPIP) is being evaluated as a potential treatment for pulmonary arterial hypertension and other rare diseases, demonstrating Insmed's forward-looking approach in drug development.
See More
Insmed Halts Lung Disorder Therapy R&D Program After Trial Failure
- R&D Program Halted: Insmed announced the suspension of its lung disorder therapy brensocatib's R&D following a mid-stage trial failure against hidradenitis suppurativa, indicating that the drug did not meet primary or secondary efficacy endpoints, which could impact the company's future product pipeline.
- Trial Results Underwhelming: In the Phase 2b CEDAR study, both 10 mg and 40 mg doses failed to meet key goals, although patients tolerated the experimental therapy well with no new safety signals, potentially shaking investor confidence in the company's R&D capabilities.
- Contribution to Scientific Understanding: Despite the disappointing results, Insmed's medical chief, Martina Flammer, expressed hope that insights gained from this study will contribute to the broader scientific understanding of hidradenitis suppurativa, demonstrating the company's ongoing commitment to scientific research.
- Market Reaction: The suspension of this R&D program may negatively affect Insmed's stock price, especially after the company secured approval for brensocatib as a treatment for non-cystic fibrosis bronchiectasis in 2025, leading investors to reassess the company's market outlook.
See More
Insmed Halts Brinsupri Development for HS After Trial Failure
- Trial Failure: Insmed has halted the development of Brinsupri for hidradenitis suppurativa (HS) after it failed to meet efficacy endpoints in a mid-stage trial, with both 10mg and 40mg doses not outperforming placebo, indicating significant challenges for the company's future R&D direction.
- Efficacy Data Disclosure: The CEDAR study revealed that Brinsupri achieved only a 45.5% and 40.3% reduction in abscess and nodule counts, respectively, compared to a 57.1% reduction in the placebo group, failing to meet both primary and secondary endpoints, which poses a substantial challenge to Insmed's market confidence.
- Market Expansion Setback: Despite receiving approval in 2025 for non-cystic fibrosis bronchiectasis, this failure may hinder Brinsupri's expansion plans in the HS market, as analysts believe there is insufficient preclinical evidence to support the drug's mechanism of action in HS.
- Analyst Sentiment: Analysts generally believe that the trial results will not significantly impact investor sentiment towards Insmed, instead shifting focus to Brinsupri's market performance in bronchiectasis, with projections indicating potential sales of $5.5 billion by 2031.
See More
Insmed to Announce Q1 Earnings on May 7th
- Earnings Announcement: Insmed (INSM) is set to release its Q1 earnings on May 7th before market open, with consensus EPS estimate at -$0.98 and revenue estimate at $300.8 million, which could provide some support for the stock price if met.
- Historical Performance: Over the past year, Insmed has beaten EPS estimates 50% of the time and revenue estimates 75% of the time, indicating a relatively strong performance in managing market expectations, which may bolster investor confidence.
- Estimate Revision Trends: In the last three months, EPS estimates have seen 2 upward revisions and 5 downward revisions, while revenue estimates have experienced 4 upward revisions and 3 downward revisions, reflecting market divergence on the company's future performance, warranting close attention to the earnings results.
- Pipeline Developments: Despite setbacks in the mid-stage trial for a skin disorder candidate, the potential label expansion for ARIKAYCE is viewed as a positive signal, which could provide new momentum for the company's future growth and enhance market expectations for its product pipeline.
See More
Insmed Partners with Ty Pennington to Raise Awareness of Bronchiectasis
- Initiative Launch: Insmed collaborates with Emmy-winning host Ty Pennington to launch the 'Suspect Bronchiectasis' educational initiative aimed at enhancing awareness and diagnosis of bronchiectasis, helping patients better understand their respiratory symptoms.
- Symptom Overlap Issue: Symptoms of bronchiectasis often overlap with chronic obstructive pulmonary disease (COPD) or asthma, leading many patients to miss timely diagnoses, highlighting the need for deeper analysis of respiratory symptoms.
- Personal Story Sharing: Pennington shares his experience caring for his mother, who has battled bronchiectasis for nearly 20 years, aiming to inspire more individuals to focus on their health and engage in deeper conversations with their healthcare providers.
- Company Mission Reinforcement: Insmed's Chief Medical Officer, Dr. Flammer, emphasizes that increasing awareness of bronchiectasis helps patients communicate more confidently with doctors, thereby accelerating the diagnostic process and improving patient quality of life.
See More
Insmed Launches Educational Initiative for Bronchiectasis Awareness
- Initiative Launch: Insmed collaborates with Emmy-winning host Ty Pennington to launch the 'Suspect Bronchiectasis' initiative, aimed at raising public awareness and promoting early diagnosis of bronchiectasis to improve patient quality of life.
- Symptom Overlap Issue: Symptoms of bronchiectasis often overlap with chronic obstructive pulmonary disease (COPD) or asthma, leading to many patients going unrecognized for years, highlighting the importance of understanding respiratory symptoms for timely treatment.
- Public Engagement Boost: Ty Pennington increases visibility for this chronic lung condition by sharing his experience caring for his mother, encouraging more individuals to pay attention to their health and consult pulmonologists for necessary testing.
- Importance of Health Education: This initiative not only raises awareness of bronchiectasis but also emphasizes the significance of communicating with healthcare professionals, aiming to reduce the long-term impact of the disease through early diagnosis and intervention.
See More
Insmed Presents New Data Supporting BRINSUPRI® Impact on Respiratory Symptoms
- Research Presentation: Insmed will present six abstracts at the 2026 American Thoracic Society International Conference, showcasing the company's ongoing innovation and commitment in the respiratory disease sector.
- Clinical Trial Advancements: The Phase 3b ENCORE study will highlight ARIKAYCE®'s potential early application in treating patients with newly diagnosed Mycobacterium avium complex lung infections, which could alter existing treatment pathways.
- Quality Improvement Funding: Insmed is providing an independent research grant to the American Thoracic Society aimed at improving bronchiectasis diagnosis, expected to enhance patient care quality by identifying misdiagnosed patients through electronic health record studies.
- New Drug Development Updates: Investigational treprostinil palmitil inhalation powder (TPIP) is being evaluated as a potential treatment for pulmonary arterial hypertension and other rare diseases, demonstrating Insmed's forward-looking approach in drug development.
See More
Insmed Halts Lung Disorder Therapy R&D Program After Trial Failure
- R&D Program Halted: Insmed announced the suspension of its lung disorder therapy brensocatib's R&D following a mid-stage trial failure against hidradenitis suppurativa, indicating that the drug did not meet primary or secondary efficacy endpoints, which could impact the company's future product pipeline.
- Trial Results Underwhelming: In the Phase 2b CEDAR study, both 10 mg and 40 mg doses failed to meet key goals, although patients tolerated the experimental therapy well with no new safety signals, potentially shaking investor confidence in the company's R&D capabilities.
- Contribution to Scientific Understanding: Despite the disappointing results, Insmed's medical chief, Martina Flammer, expressed hope that insights gained from this study will contribute to the broader scientific understanding of hidradenitis suppurativa, demonstrating the company's ongoing commitment to scientific research.
- Market Reaction: The suspension of this R&D program may negatively affect Insmed's stock price, especially after the company secured approval for brensocatib as a treatment for non-cystic fibrosis bronchiectasis in 2025, leading investors to reassess the company's market outlook.
See More
Insmed Halts Brinsupri Development for HS After Trial Failure
- Trial Failure: Insmed has halted the development of Brinsupri for hidradenitis suppurativa (HS) after it failed to meet efficacy endpoints in a mid-stage trial, with both 10mg and 40mg doses not outperforming placebo, indicating significant challenges for the company's future R&D direction.
- Efficacy Data Disclosure: The CEDAR study revealed that Brinsupri achieved only a 45.5% and 40.3% reduction in abscess and nodule counts, respectively, compared to a 57.1% reduction in the placebo group, failing to meet both primary and secondary endpoints, which poses a substantial challenge to Insmed's market confidence.
- Market Expansion Setback: Despite receiving approval in 2025 for non-cystic fibrosis bronchiectasis, this failure may hinder Brinsupri's expansion plans in the HS market, as analysts believe there is insufficient preclinical evidence to support the drug's mechanism of action in HS.
- Analyst Sentiment: Analysts generally believe that the trial results will not significantly impact investor sentiment towards Insmed, instead shifting focus to Brinsupri's market performance in bronchiectasis, with projections indicating potential sales of $5.5 billion by 2031.
See More
